Gilead Sciences, Inc. (GILD) Bulls Eye a Bigger Bounce

Gilead Sciences, Inc. call volume is trading at two times the intraday average

by Karee Venema

Published on Dec 5, 2014 at 1:15 PM
Updated on Apr 20, 2015 at 5:32 PM

Although Gilead Sciences, Inc. (NASDAQ:GILD) stumbled after hitting a record peak of $116.83 in late October, the stock found support near the century mark, and was last seen trading at $105.11 -- up 3.2% on the day. Amid today's analyst-induced bounce, calls are crossing the tape at two times the average intraday pace -- a change of pace to the withstanding trend -- with a number of speculators rolling the dice on an extended rise over the next six weeks.

GILD's most active option is the at-the-money January 2015 105-strike call, where 7,280 contracts are on the tape. The majority of the action has occurred on the ask side, and implied volatility is up 1.9 percentage points -- pointing to the purchase of new positions.

Today's call buyers will profit if Gilead Sciences, Inc. (NASDAQ:GILD) is resting above breakeven at $108.98 (strike plus the volume-weighted average price of $3.98) at the close on Friday, Jan. 16 -- when the back-month options expire. Profit is theoretically unlimited beyond here, while losses are capped at the initial premium paid, should the stock settle south of the strike at expiration. At last check, delta on the call was docked at 0.52, suggesting a 52% chance the option will be in the money at expiration.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.